[Pubmed] Treatment patterns in myasthenia gravis: a United States health claims analysis
-
Auteur du sujet - Ami(e) de Diamant
- Messages : 3074
- Enregistré le : 31 mai 2020 09:57
- 3
- Zodiaque :
- Âge : 20
- Contact :
[Pubmed] Treatment patterns in myasthenia gravis: a United States health claims analysis
Muscle Nerve. 2023 Jan 31. doi: 10.1002/mus.27791. Online ahead of print.
ABSTRACT
INTRODUCTION/AIMS: Limited knowledge exists on treatment patterns in clinical practice in patients with myasthenia gravis (MG). This study examined MG treatment patterns in the US.
METHODS: Adult patients newly diagnosed with MG were identified from the IBM MarketScan insurance claims database. Patients with ≥2 MG International Classification of Disease diagnosis codes ≥3 months apart were retrospectively followed from the date of their first MG diagnosis record or start of treatment with acetylcholinesterase inhibitors (AChEI), intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig), or plasma exchange (PLEX) therapy. Based on treatment received at any time during the follow-up period, patients were segmented into six main treatment cohorts. Exacerbations, and use of IVIg, SCIg or PLEX after the index date, were identified.
RESULTS: During 2010-2019, 7194 patients were followed for up to 10 years (median 2.3 years). Of 6539 treated patients, 6462 (99%) were ever treated with AChEI and/or corticosteroids (CS); 95% were first treated with AChEI and/or CS only; 33% received at least 1 non-steroid immunosuppressive treatment (IST) and 2% received a biologic. During treatment with first IST (n=2166), patients experienced 42% and 94% higher incidence rates of exacerbations and IVIg, respectively, compared with AChEI and/or CS (n=6242), and 33% and 23% higher, respectively, compared with a second IST (n=353).
DISCUSSION: Many patients experienced exacerbations and received rescue therapy despite treatment, suggesting current treatments may not provide adequate disease control for some patients, and additional treatment options should be explored. This article is protected by copyright. All rights reserved.
PMID:36721910 | DOI:10.1002/mus.27791
Source: https://pubmed.ncbi.nlm.nih.gov/3672191 ... t6+86293ac
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page
Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com
Bonne lecture...
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page
Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com
Bonne lecture...